ArticleBMJ open2025
Scalp acupoint catgut embedding combined with topical 5% minoxidil tincture to improve male androgenetic alopecia: protocol for a randomised controlled trial.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAndrogenetic alopecia (AGA), the most prevalent form of hair loss in clinical practice, affects 21.3% of the male population in China. The condition significantly impacts patients' self-perception, psychological well-being and quality of life. Preliminary evidence suggests that acupoint catgut embedding (ACE) may offer therapeutic benefits for AGA. This randomised controlled trial aims to evaluate the efficacy and safety of ACE combined with topical 5% minoxidil tincture in managing AGA. METHODS AND ANALYSIS: This is a single-centre, prospective, double-blind, randomised controlled trial. A total of 70 male patients with AGA will be randomly allocated to either the ACE group (ACE combined with topical minoxidil) or the control group (sham ACE combined with topical minoxidil) at a 1:1 ratio. All participants will receive standardised topical 5% minoxidil therapy during the 24-week intervention period, with concomitant administration of either ACE or sham ACE (needle insertion mimicking ACE protocol without suture implantation) at 4-week intervals. Post-treatment follow-up will extend for 24 weeks. The primary outcome measure will be the change in the number of target area hair count (TAHC) after 24 weeks of treatment compared with the baseline. Secondary outcomes will include hair growth assessment, changes in the number of TAHC, changes in the diameter of target area cumulative non-vellus hair width and changes in sex hormone levels. Statistical significance will be defined as a two-sided p value<0.05. ETHICS AND DISSEMINATION: This study has been approved by the clinical research ethics committee of China-Japan Friendship Hospital (project number: 2023-KY-304) and requires written informed consent from the patients. The results will be published in a peer-reviewed academic journal. TRIAL REGISTRATION NUMBER: ChiCTR2300078123.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.